Literature DB >> 23359299

Gene mutations of acute myeloid leukemia in the genome era.

Tomoki Naoe1, Hitoshi Kiyoi.   

Abstract

Ten years ago, gene mutations found in acute myeloid leukemia (AML) were conceptually grouped into class I mutation, which causes constitutive activation of intracellular signals that contribute to the growth and survival, and class II mutation, which blocks differentiation and/or enhance self-renewal by altered transcription factors. A cooperative model between two classes of mutations has been suggested by murine experiments and partly supported by epidemiological findings. In the last 5 years, comprehensive genomic analysis proceeded to find new gene mutations, which are found in the epigenome-associated enzymes and the molecules never noticed so far. These new mutations apparently increase the complexity and heterogeneity of AML. Although a long list of gene mutations might have been compiled, the entire picture of molecular pathogenesis in AML remains to be elucidated because gene rearrangement, gene copy number, DNA methylation and expression profiles are not fully studied in conjunction with gene mutations. Comprehensive genome research will deepen the understanding of AML to promote the development of new classification and treatment. This review focuses on gene mutations that were recently discovered by genome sequencing.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23359299     DOI: 10.1007/s12185-013-1257-4

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  94 in total

1.  Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype.

Authors:  Vera Grossmann; Enrico Tiacci; Antony B Holmes; Alexander Kohlmann; Maria Paola Martelli; Wolfgang Kern; Ariele Spanhol-Rosseto; Hans-Ulrich Klein; Martin Dugas; Sonja Schindela; Vladimir Trifonov; Susanne Schnittger; Claudia Haferlach; Renato Bassan; Victoria A Wells; Orietta Spinelli; Joseph Chan; Roberta Rossi; Stefano Baldoni; Luca De Carolis; Katharina Goetze; Hubert Serve; Rudolf Peceny; Karl-Anton Kreuzer; Daniel Oruzio; Giorgina Specchia; Francesco Di Raimondo; Francesco Fabbiano; Marco Sborgia; Arcangelo Liso; Laurent Farinelli; Alessandro Rambaldi; Laura Pasqualucci; Raul Rabadan; Torsten Haferlach; Brunangelo Falini
Journal:  Blood       Date:  2011-10-19       Impact factor: 22.113

2.  SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes.

Authors:  Valeria Visconte; Heesun J Rogers; Jarnail Singh; John Barnard; Manoj Bupathi; Fabiola Traina; James McMahon; Hideki Makishima; Hadrian Szpurka; Anna Jankowska; Andres Jerez; Mikkael A Sekeres; Yogen Saunthararajah; Anjali S Advani; Edward Copelan; Haruhiko Koseki; Kyoichi Isono; Richard A Padgett; Sami Osman; Kazunori Koide; Christine O'Keefe; Jaroslaw P Maciejewski; Ramon V Tiu
Journal:  Blood       Date:  2012-07-23       Impact factor: 22.113

Review 3.  Deregulated transcription factors in leukemia.

Authors:  Yutaka Shima; Issay Kitabayashi
Journal:  Int J Hematol       Date:  2011-08-09       Impact factor: 2.490

4.  Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes.

Authors:  Brady L Stein; Donna M Williams; Christine O'Keefe; Ophelia Rogers; Roxann G Ingersoll; Jerry L Spivak; Amit Verma; Jarek P Maciejewski; Michael A McDevitt; Alison R Moliterno
Journal:  Haematologica       Date:  2011-06-28       Impact factor: 9.941

Review 5.  IDH mutations in glioma and acute myeloid leukemia.

Authors:  Lenny Dang; Shengfang Jin; Shinsan M Su
Journal:  Trends Mol Med       Date:  2010-08-05       Impact factor: 11.951

Review 6.  Acute myeloid leukaemia.

Authors:  Elihu Estey; Hartmut Döhner
Journal:  Lancet       Date:  2006-11-25       Impact factor: 79.321

7.  DNMT3A mutations in acute myeloid leukemia.

Authors:  Timothy J Ley; Li Ding; Matthew J Walter; Michael D McLellan; Tamara Lamprecht; David E Larson; Cyriac Kandoth; Jacqueline E Payton; Jack Baty; John Welch; Christopher C Harris; Cheryl F Lichti; R Reid Townsend; Robert S Fulton; David J Dooling; Daniel C Koboldt; Heather Schmidt; Qunyuan Zhang; John R Osborne; Ling Lin; Michelle O'Laughlin; Joshua F McMichael; Kim D Delehaunty; Sean D McGrath; Lucinda A Fulton; Vincent J Magrini; Tammi L Vickery; Jasreet Hundal; Lisa L Cook; Joshua J Conyers; Gary W Swift; Jerry P Reed; Patricia A Alldredge; Todd Wylie; Jason Walker; Joelle Kalicki; Mark A Watson; Sharon Heath; William D Shannon; Nobish Varghese; Rakesh Nagarajan; Peter Westervelt; Michael H Tomasson; Daniel C Link; Timothy A Graubert; John F DiPersio; Elaine R Mardis; Richard K Wilson
Journal:  N Engl J Med       Date:  2010-11-10       Impact factor: 91.245

Review 8.  Dysregulation of the C/EBPalpha differentiation pathway in human cancer.

Authors:  Steffen Koschmieder; Balazs Halmos; Elena Levantini; Daniel G Tenen
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

9.  IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

Authors:  Peter Paschka; Richard F Schlenk; Verena I Gaidzik; Marianne Habdank; Jan Krönke; Lars Bullinger; Daniela Späth; Sabine Kayser; Manuela Zucknick; Katharina Götze; Heinz-A Horst; Ulrich Germing; Hartmut Döhner; Konstanze Döhner
Journal:  J Clin Oncol       Date:  2010-06-21       Impact factor: 50.717

Review 10.  Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.

Authors:  Véronique Gelsi-Boyer; Mandy Brecqueville; Raynier Devillier; Anne Murati; Marie-Joelle Mozziconacci; Daniel Birnbaum
Journal:  J Hematol Oncol       Date:  2012-03-21       Impact factor: 17.388

View more
  25 in total

1.  Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia.

Authors:  Stephen A Strickland; Aaron C Shaver; Michael Byrne; Robert D Daber; P Brent Ferrell; David R Head; Sanjay R Mohan; Claudio A Mosse; Tamara K Moyo; Thomas P Stricker; Cindy Vnencak-Jones; Michael R Savona; Adam C Seegmiller
Journal:  Leuk Res       Date:  2018-01-02       Impact factor: 3.156

Review 2.  Novel therapeutic strategy based on genetic and epigenetic abnormalities for myeloid neoplasms.

Authors:  Takahiro Yamauchi
Journal:  Int J Clin Oncol       Date:  2019-05-18       Impact factor: 3.402

3.  Somatic mutations in murine models of leukemia and lymphoma: Disease specificity and clinical relevance.

Authors:  Liat Goldberg; Sheryl M Gough; Fan Lee; Christine Dang; Robert L Walker; Yuelin J Zhu; Sven Bilke; Marbin Pineda; Masahiro Onozawa; Yang Jo Chung; Paul S Meltzer; Peter D Aplan
Journal:  Genes Chromosomes Cancer       Date:  2017-03-31       Impact factor: 5.006

Review 4.  Small RNA as a regulator of hematopoietic development, immune response in infection and tumorigenesis.

Authors:  Kazuki Okuyama; Jun Ogata; Natsuko Yamakawa; Bidisha Chanda; Ai Kotani
Journal:  Int J Hematol       Date:  2014-04-01       Impact factor: 2.490

Review 5.  Multistep tumorigenesis in peripheral T cell lymphoma.

Authors:  Mamiko Sakata-Yanagimoto
Journal:  Int J Hematol       Date:  2015-01-28       Impact factor: 2.490

6.  A structured population model of clonal selection in acute leukemias with multiple maturation stages.

Authors:  Tommaso Lorenzi; Anna Marciniak-Czochra; Thomas Stiehl
Journal:  J Math Biol       Date:  2019-07-26       Impact factor: 2.259

7.  Possible role of intragenic DNA hypermethylation in gene silencing of the tumor suppressor gene NR4A3 in acute myeloid leukemia.

Authors:  Ryo Shimizu; Tomoya Muto; Kazumasa Aoyama; Kwangmin Choi; Masahiro Takeuchi; Shuhei Koide; Nagisa Hasegawa; Yusuke Isshiki; Emi Togasaki; Chika Kawajiri-Manako; Yuhei Nagao; Shokichi Tsukamoto; Shio Sakai; Yusuke Takeda; Naoya Mimura; Chikako Ohwada; Emiko Sakaida; Tohru Iseki; Daniel T Starczynowski; Atsushi Iwama; Koutaro Yokote; Chiaki Nakaseko
Journal:  Leuk Res       Date:  2016-09-26       Impact factor: 3.156

8.  A panoramic view of acute myeloid leukemia.

Authors:  Sai-Juan Chen; Yang Shen; Zhu Chen
Journal:  Nat Genet       Date:  2013-06       Impact factor: 38.330

9.  Internal tandem duplication of FLT3 deregulates proliferation and differentiation and confers resistance to the FLT3 inhibitor AC220 by Up-regulating RUNX1 expression in hematopoietic cells.

Authors:  Tomohiro Hirade; Mariko Abe; Chie Onishi; Takeshi Taketani; Seiji Yamaguchi; Seiji Fukuda
Journal:  Int J Hematol       Date:  2015-11-21       Impact factor: 2.490

Review 10.  Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia.

Authors:  Akihiro Takeshita
Journal:  Int J Hematol       Date:  2013-05-26       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.